Implantation of Implantable Cardioverter Defibrillators in Kazakhstan.


Journal

Global heart
ISSN: 2211-8179
Titre abrégé: Glob Heart
Pays: England
ID NLM: 101584391

Informations de publication

Date de publication:
2022
Historique:
received: 03 05 2021
accepted: 16 04 2022
entrez: 19 5 2022
pubmed: 20 5 2022
medline: 21 5 2022
Statut: epublish

Résumé

Implantation of implantable cardioverter-defibrillators (ICD) has increased significantly over the past decade. However, limited data exist regarding practices and policies of ICD implantations in Kazakhstan. We aimed to provide an overview of the current use of ICD in Kazakhstan. Using the Unified Healthcare Information System database of the entire Kazakh adult population, statistical and cost data of ICD implantations in 2017-2019 were evaluated. Cardiologists and electrophysiologists working in cardio surgery centers and departments were asked to go through an online survey focused on subcutaneous-ICD (S-ICD) experience. Implantation of traditional transvenous cardioverter-defibrillators for residents of Kazakhstan is fully reimbursed. A total of 2,263 ICD interventions (2,252 new implantations and 11 reimplantations) were performed across the country during the study period. According to the tariffs approved by the Ministry of Health, the reimbursement cost for one ICD case is about 14,061.80 US dollars. The survey showed that only two hospitals have implanted S-ICDs. Among the main reasons why S-ICD is not widely used in the country the following were named: lack of trained staff (61.1% of respondents); the cost of device and lack of reimbursement (38.7%); and lack of pacing function (27.8%). The number of ICD implantation in Kazakhstan is steadily continuing to grow, although, compared to developed countries, the implantation rate especially for S-ICD remains low. There is a need in deliberate strategies to remove policy barriers for implementation the most innovative cardiac implantable electronic devices implantations such as S-ICD in the country.

Sections du résumé

Background and Objectives
Implantation of implantable cardioverter-defibrillators (ICD) has increased significantly over the past decade. However, limited data exist regarding practices and policies of ICD implantations in Kazakhstan. We aimed to provide an overview of the current use of ICD in Kazakhstan.
Methods
Using the Unified Healthcare Information System database of the entire Kazakh adult population, statistical and cost data of ICD implantations in 2017-2019 were evaluated. Cardiologists and electrophysiologists working in cardio surgery centers and departments were asked to go through an online survey focused on subcutaneous-ICD (S-ICD) experience.
Results
Implantation of traditional transvenous cardioverter-defibrillators for residents of Kazakhstan is fully reimbursed. A total of 2,263 ICD interventions (2,252 new implantations and 11 reimplantations) were performed across the country during the study period. According to the tariffs approved by the Ministry of Health, the reimbursement cost for one ICD case is about 14,061.80 US dollars. The survey showed that only two hospitals have implanted S-ICDs. Among the main reasons why S-ICD is not widely used in the country the following were named: lack of trained staff (61.1% of respondents); the cost of device and lack of reimbursement (38.7%); and lack of pacing function (27.8%).
Conclusion
The number of ICD implantation in Kazakhstan is steadily continuing to grow, although, compared to developed countries, the implantation rate especially for S-ICD remains low. There is a need in deliberate strategies to remove policy barriers for implementation the most innovative cardiac implantable electronic devices implantations such as S-ICD in the country.

Identifiants

pubmed: 35586742
doi: 10.5334/gh.1119
pmc: PMC9104561
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

30

Informations de copyright

Copyright: © 2022 The Author(s).

Déclaration de conflit d'intérêts

The authors have no competing interests to declare.

Références

Europace. 2015 Feb;17(2):174-86
pubmed: 25480942
Rev Esp Cardiol (Engl Ed). 2020 Dec;73(12):1026-1037
pubmed: 33039380
Heart Rhythm. 2018 Oct;15(10):e73-e189
pubmed: 29097319
Eur Heart J. 2001 Jun;22(12):990-6
pubmed: 11428834
Europace. 2015 Nov;17(11):1601-87
pubmed: 26318695
J Am Heart Assoc. 2015 Nov 06;4(11):
pubmed: 26546574
Open Heart. 2015 Feb 17;2(1):e000198
pubmed: 25745566
Eur Heart J. 2017 Jun 07;38(22):1738-1746
pubmed: 28329280
J Med Econ. 2021 Jan-Dec;24(1):173-180
pubmed: 33471579
Europace. 2015 Aug;17 Suppl 4:iv1-72
pubmed: 26286028
J Interv Card Electrophysiol. 2008 Jun;22(1):65-70
pubmed: 18324458
Korean Circ J. 2019 Sep;49(9):841-852
pubmed: 31074230
Acta Cardiol Sin. 2014 Jan;30(1):22-8
pubmed: 27122764
Cardiovasc Ther. 2017 Jun;35(3):
pubmed: 28129469
Europace. 2016 Sep;18(9):1434-9
pubmed: 27582309
PLoS One. 2020 Nov 19;15(11):e0241697
pubmed: 33211698
JACC Clin Electrophysiol. 2017 Dec 26;3(13):1475-1483
pubmed: 29759827
J Am Coll Cardiol. 2011 Aug 30;58(10):1001-6
pubmed: 21867833
J Arrhythm. 2019 Oct 06;36(1):153-163
pubmed: 32071634

Auteurs

Temirkhan Begisbayev (T)

Kazakhstans Medical University "KSPH", Almaty, Kazakhstan.

Lyazzat Kosherbayeva (L)

Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Al-Farabi Kazakh National University, Almaty, Kazakhstan.

Valikhan Akhmetov (V)

Kazakhstans Medical University "KSPH", Almaty, Kazakhstan.

Dmitry Khvan (D)

National Medical Research Center named after Academician E. Meshalkin, Ministry of Health of the Russian Federation, Kazakhstan.

Marzhan Brimzhanova (M)

Kazakhstans Medical University "KSPH", Almaty, Kazakhstan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH